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Summary
Sentinel lymph node biopsy (SLNB) is the gold standard in surgical treatment of early-stage breast cancer. Since June 
2015 we have been performing SLNB in our hospital with a new technique which uses superparamagnetic iron oxide (SPIO), 
commercially known as Sienna+, as tracer and device-magnetometer (SentiMag) for locating axillary lymph nodes which 
accumulated SPIO particles. Artifacts resulting from SPIO accumulation in the breast tissue were observed on post-opera-
tive breast magnetic resonace imaging (MRI) scans in all patients who underwent postoperative breast MRIs. Artifacts were 
observed on T1-weighted images, as well as on dynamic and subtraction sequences. We have designed a study that will 
include a three-year post-operative follow-up of these patients with MRI breast scans in order to evaluate presence or 
 absence of these artifacts and change of artifacts over time. Upon completion of the study indications for using magnetic 
SLNB may need to be revised.
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PLAN ISTRAŽIVANJA PRAZNIH ARTEFAKATA NA POSLIJEOPERACIJSKIM NALAZIMA 
MAGNETNE REZONANCE DOJKE NAKON PRIMJENE SUPERPARAMAGNETIČNOG ŽELJEZNOG OKSIDA 
U BIOPSIJI LIMFNG ČVORA STRAŽARA
Sažetak
Biopsija limfnog čvora stražara je zlatni standard u kirurškom liječenju ranog stadija raka dojke. Od lipnja 2015. godi-
ne, u našoj ustanovi koristi se nova metoda obilježavanja superparamagnetičnim željeznim oksidom, komercijalnog imena 
Sienna+. Za pronalaženje limfnog čvora s nakupljenim česticama željeznog oksida koristi se detektor – SentiMag. Kod bole-
snica kod kojih je učinjena poslijeoperacijska magnentna rezonanca dojki uočeni su artefakti na T1 mjerenim snimkama, a 
također i na dinamičkim i subtrakcijskim sekvencama. Osmislili smo studiju kojom će se tri godine magnetnom rezonancom 
pratiti operirane bolesnice. Odredit će se prisutnost artefakata, te njihova prisutnost tijekom vremenu. Očekuju se nove 
spoznaje korisne u biopsije limfnog čvora stražara.
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Sentinel lymph node biopsy (SLNB) today is 
the gold standard for treatment of early-stage 
breast cancer, and it is unavoidable in planning 
further therapy and/or surgical treatment (1), 
since the status of axillary lymph nodes is known 
to be the most important prognostic factor for 
these patients (2). The usual procedure includes 
using a radioisotope with or without the blue dye 
to detect a sentinel lymph node. In addition to an 
obvious down side to this procedure i.e. irradia-
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tion for the patient and medical staﬀ , there is also 
a need for very precise interdepartmental cooper-
ation with a nuclear medicine department which 
in practice, is sometimes diﬃ  cult to obtain.
The SentiMag technique is a relatively new, 
eﬀ ective radioisotope-free detection system which 
uses superparamagnetic iron oxide (SPIO), com-
mercially known as Sienna+, as tracer and device-
magnetometer (SentiMag) for locating axillary 
lymph nodes which accumulated SPIO particles. 
Sienna+ is a dark solution containing dextran-
coated SPIO particles, size of 60 nm each (3). After 
injecting the solution in subareolar region, parti-
cles drain through the lymphatics and accumu-
lates in the sentinel lymph node. This takes place 
at least 20 minutes before the actual SLNB proce-
dure. Then the probe is inserted into the incision 
and identifi es the sentinel nodes by their high 
reading on Sentimag and coloration change. Cur-
rently, there are nine studies and multicentric tri-
als showing equal value of magnetic technique 
compared to radioisotope method of locating sen-
tinel lymph nodes (4,5,6,7,8,9,10,11). The Senti-
Mag manufacturer emphasizes the proximity-
based detection of the magnetic probe, meaning 
that the probe sensitivity varies exponentially 
with distance, unlike gamma probe detects with 
linear and angular sensitivity which can result in 
receiving intermitt ent signal, making localisation 
more challenging (1).
We have been performing SLNBs in our hos-
pital since June 2015, during that period we per-
formed 320 procedures.  Upon performing post-
operative breast MRI scans for a number of these 
patients we observed void artifacts on pre and 
postcontrast T1-weighted images, as well as arti-
facts on the dynamic and subtraction sequences 
(Fig. 1). After reevaluating 9 patients with postop-
erative breast MRIs, we found artifacts on every 
performed study. These MRIs were performed in 
the time frame of 6 months after surgery, until 12 
months after surgery.
Breast MRI is an important diagnostic proce-
dure for detection of breast cancer, with a high 
sensitivity (over 90%) and as of yet still moderate 
specifi city (72%), (2).
There are no fi rm guidelines on MRI indica-
tions. According to the most recent guidelines for 
managing breast cancer patients from American 
College of Radiology (ACR) from 2013 and Euro-
pean Society for Medical Oncology (ESMO) from 
2015 (3) breast MRI is a valuable tool in detecting 
early stage disease in population with higher risk, 
which most predominantely includes women 
with genetic predisposition (4). Furthermore MRI 
breast scans are used in case where mammogra-
phy and ultrasound (US) fi ndings are inconlusive 
as can often be in women with dense breasts, and 
in case of ductal carcinoma in situ (DCIS). DCIS is 
usually seen as mammographic abnormality pre-
sented as clusters of microcalcifi cations. US is in 
many cases either inconclusive or shows only 
mild abnormaility or even normal results. Even 
though, the sensitivity of breast MRI in cases of 
DCIS may vary, it is still an important tool for de-
fi nitive diagnosis of this condition (5). Another 
important indication for breast MRI is scanning 
when there is a high suspicion of breast cancer re-
currence i.e, the recurrence of malignancy within 
the same breast at or close to the resection bed 




more than two years following surgical excision. 
The risk of local recurrence can be as high as 19% 
in the fi rst fi ve years (6). In these cases, especially 
if involving younger patients with higher percent-
age of glandular parenchyma in breasts, artifacts 
on MRI scans may result in partialy or completely 
missing the diagnosis thus postponing the needed 
treatment.
In our hospital we aim to include MRI exam 
in mos preoperative examination for every pa-
tient. Also, we use it in the follow-up of patients 
who underwent neoadjuvant chemotherapy. Fur-
thermore, it is used as a follow-up examination for 
some years after the treatment for patients with 
increased risk of recurrence.There are as of yet no 
studies describing presence or absence of artifacts 
in patients who underwent SLNB using Sienna+ 
tracer in longer follow-up period. After reviewing 
the literature we have come across an abstract of a 
single study that followed small number of pa-
tients up to 24 months after surgery(7).
There is a defi nite need to obtain more data 
with regards to this issue. We have designed a 
study, in which we plan to perform preoperative 
MRI scan and at 12, 18, 24, 26 and 36 months. The 
scans will be evaluated in order to confi rm or ex-
clude the long standing presence of these artifacts 
on MRI scans including T1-weighted images as 
well as dynamic and subtraction sequences. Other 
parameters which will be investigated are the size 
of the artifact, location of the artifact in the breast 
tissue, change of artifact size over time. We also 
plan to take patients age and percentage of glan-
dular parenchyma shown on pre-operative scans 
into account and try to evaluate if it would be pos-
sible to single out patients who are expected to 
show larger artifacts on postoperative MRI breast 
scans.
We believe this study will generate valuable 
data for the use of the technology which enabled a 
more widely used conservative axillary treatment 
for early breast cancer. The study was approved 
by the Hospital Ethics Committ ee.
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